<scp>OCTET</scp>‐<scp>CY</scp>: a phase <scp>II</scp> study to investigate the efficacy of post‐transplant cyclophosphamide as sole graft‐versus‐host prophylaxis after allogeneic peripheral blood stem cell transplantation

Abstract

Post-transplant cyclophosphamide as sole IS in PBSCT is feasible and allows rapid immune recovery. Increased rates of severe acute GvHD explain the observed NRM and may advise a temporary combination partner such as mTor-inhibitors in the PBSCT setting.

References

Page 1

	Year	Citations
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report Madan Jagasia, Hildegard Greinix, Mukta Arora, Biology of Blood and Marrow Transplantation Solid Organ TransplantationImmunologyPathologySurgeryChronic Gvhd	2014	5.2K
1994 Consensus Conference on Acute GVHD Grading. Donna Przepiorka, Daniel Weisdorf, Peyton Martin, PubMed	1995	5.1K
Optimal two-stage designs for phase II clinical trials Richard Simon Controlled Clinical Trials Clinical Trial ManagementClinical TrialsRandomized Controlled TrialBiostatisticsDrug Trial	1989	3.6K
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report Alexandra H. Filipovich, Daniel J. Weisdorf, Steven Z. Pavletic, Biology of Blood and Marrow Transplantation	2005	3.5K
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide Leo Luznik, Paul V. O’Donnell, Heather J. Symons, Biology of Blood and Marrow Transplantation	2008	1.9K
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia Rainer Storb, H. Joachim Deeg, John Whitehead, New England Journal of Medicine	1986	1.4K
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors Claudio Anasetti, Brent R. Logan, Stephanie J. Lee, New England Journal of Medicine	2012	882
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Richard A. Nash, Joseph H. Antin, Chatchada Karanes, PubMed	2000	591
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Voravit Ratanatharathorn, Richard A. Nash, Donna Przepiorka, PubMed	1998	568
T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation Asad Bashey, Xu Zhang, Connie A. Sizemore, Journal of Clinical Oncology	2013	495

Page 1